Effect of Lutetium-177 Dota Octreotate Peptide Receptor Radionuclide Therapy in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome Refractory to Somatostatin Analogues

被引：0
作者：
Koffas, Apostolos
Popat, Rickin
Demetriou, George
Quigley, Ann-Marie
Navalkissoor, Shaunak
Caplin, Martyn
Toumpanakis, Christos
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)30774-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1059
引用
收藏
页码：S208 / S208
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors
    Kobayashi, Noritoshi
    Takano, Shoko
    Ito, Kenichi
    Sugiura, Madoka
    Ogawa, Matsuyoshi
    Takeda, Yuma
    Okubo, Naoki
    Suzuki, Akihiro
    Tokuhisa, Motohiko
    Kaneta, Tomohiro
    Utsunomiya, Daisuke
    Hata, Masaharu
    Inoue, Tomio
    Hosono, Makoto
    Kinuya, Seigo
    Ichikawa, Yasushi
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (12) : 1332 - 1341
  • [32] Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival
    Loeser, Anastassia
    Schwarzenboeck, Sarah M.
    Heuschkel, Martin
    Willenberg, Holger S.
    Krause, Bernd J.
    Kurth, Jens
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (03) : 236 - 246
  • [33] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
    Jiang, Yuanyuan
    Liu, Qingxing
    Wang, Guochang
    Sui, Huimin
    Wang, Rongxi
    Wang, Jiarou
    Zhang, Jingjing
    Zhu, Zhaohui
    Chen, Xiaoyuan
    THERANOSTICS, 2022, 12 (15): : 6437 - 6445
  • [34] 177Lutetium-Peptide Receptor Radionuclide Therapy (PRRT) safety assessment in patients with refractory Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NETs)
    van Bogaert, C.
    Mileva, M.
    Marin, G.
    Levillain, H.
    Artigas-Guix, C.
    Critchi, G.
    Marin, C.
    Hendlisz, A.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 161 - 161
  • [35] Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
    Sabet, Amir
    Dautzenberg, Kristina
    Haslerud, Torjan
    Aouf, Anas
    Sabet, Amin
    Simon, Birgit
    Mayer, Karin
    Biersack, Hans-Juergen
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) : 1238 - 1246
  • [36] Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
    Amir Sabet
    Kristina Dautzenberg
    Torjan Haslerud
    Anas Aouf
    Amin Sabet
    Birgit Simon
    Karin Mayer
    Hans-Jürgen Biersack
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1238 - 1246
  • [37] Lutetium-177 Dotatate Peptide Receptor Radionuclide Therapy in metastatic pheochromocytoma and paraganglioma: Experience in our center
    Negre, M.
    Guardeno, R.
    Biarnes, J.
    Recasens, M.
    Rubio, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 210 - 210
  • [38] 177Lu-DOTA-octreotate Therapy of Advanced Pancreatic Neuroendocrine Tumors - a Single Centre Experience
    Fross-Baron, K.
    Garske-Roman, U.
    Welin, S.
    Granberg, D.
    Eriksson, B.
    Sandstrom, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S401 - S402
  • [39] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Minczeles, Noemie S.
    Feelders, Richard A.
    de Herder, Wouter W.
    Hofland, Johannes
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09) : E3665 - E3672
  • [40] Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumors
    Almeamar, H.
    Cullen, L.
    Murphy, D.
    Crowley, R.
    Skehan, S.
    Welin, S.
    O'Shea, D.
    O'Toole, D.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 136 - 136
12345